MedTrace Logo

Right Ventricular Function in Patients Taking Carfilzomib

NCT06568952 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2024-08-23

No results posted yet for this study

Summary

Patients treated for multiple myeloma in the second line with carfilzomib may develop pulmonary hypertension. This is well documented in the literature. However, there are no studies looking at right ventricular function in these patients, both before and during treatment.

Conditions

  • Pulmonary Hypertension

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Simon Valentin, MD · Université de Lorraine, Département de Pneumologie, CHRU NANCY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-30
Primary Completion
2024-06-30
Completion
2024-07-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06568952 on ClinicalTrials.gov